glp 1 drugs and breast cancer Glucagon-like peptide receptor agonists risk: advancing precision medicine through mechanistic understanding and clinical evidence | Biomarker Research GLP-1 drugs cut breast cancer

10.1038/nature07455 [DOI] [PMC free article] [PubMed] [Google Scholar] Ledford H

Brown adipose tissue thermogenesis in the resistance to and reversal of obesity: a potential new mechanism contributing to the metabolic benefits of proglucagon-derived peptides

Patients who suffer from the adverse effects of the weight loss injections may file for compensation

[DOI] [PubMed] [Google Scholar] 57.Gerstein H.C., Colhoun H.M., Dagenais G.R., Diaz R., Lakshmanan M., Pais P., Probstfield J., Botros F.T., Riddle M.C., Rydn L., et al

Rats that receive a single subcutaneous dose of glucagon exhibit a sharp rise in metabolic rate, which is consistent with this theory [36]

These protective effects were consistent regardless of whether the patients had diabetes or obesity